Chromatin Composition Alterations and the Critical Role of MeCP2 for Epigenetic Silencing of Progesterone Receptor-B Gene in Endometrial Cancers

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2014 Feb 18

PMID 24531693

Citations 5

Authors

Yongli Chu

Yanlin Wang

Guanghua Zhang

Haibin Chen

Sean C Dowdy

Yuning Xiong

Fengming Liu

Run Zhang

Jinping Li

Shi-Wen Jiang

Affiliations

Soon will be listed here.

Abstract

Objective: To understand the epigenetic mechanism underlying the PR-B gene silencing in endometrial cancer (EC) cells, we compared the chromatin composition between transcriptionally active and silenced PR-B genes in EC cell lines and cancer tissues.

Methods: Chromatin Immunoprecipitation (ChIP) assay was performed to measure MBD occupancy and histone acetylation/methylation in transcriptionally active and silenced PR-B genes. PR-B-positive/-negative, as well as epigenetic inhibitor-treated/-untreated EC cells were used as study models. Real-time polymerase chain reaction (PCR) and Western blot analysis were applied to measure the mRNA and protein levels of PR-B, MBD, and histones.

Results: A close association among PR-B methylation, MBD binding and PR-B gene silencing was observed. Treatment with epigenetic inhibitors led to dynamic changes in the PR-B chromatin composition and gene expression. Increased H3/H4 acetylation and H3-K4 methylation, and decreased H3-K9 methylation were found to be associated with re-activation of silenced PR-B genes. MeCP2 knockdown resulted in a decreased MeCP2 binding to PR-B genes and an increased PR-B expression. ChIP analysis of MeCP2 binding to PR-B genes in the PR-B-positive/-negative EC samples confirmed the significant role of MeCP2 in PR-B silencing.

Conclusion: PR-B gene expression is regulated by a concerted action of epigenetic factors including DNA methylation, MBD binding, and histone modifications. MeCP2 occupancy of PR-B genes plays a critical role in PR-B gene silencing. These findings enriched our knowledge of the epigenetic regulation of PR-B expression in EC, and suggested that the epigenetic re-activation of PR-B could be explored as a potential strategy to sensitize the PR-B-negative endometrial cancers to progestational therapy.

Citing Articles

Research Progress of DNA Methylation Markers for Endometrial Carcinoma Diagnosis.

Zheng H, Yu C, Yang L, Zhou F, Liu A J Cancer. 2025; 16(3):812-820.

PMID: 39781343 PMC: 11705058. DOI: 10.7150/jca.104214.

The role of epigenetic mechanisms in the regulation of gene expression in the cyclical endometrium.

Retis-Resendiz A, Gonzalez-Garcia I, Leon-Juarez M, Camacho-Arroyo I, Cerbon M, Vazquez-Martinez E Clin Epigenetics. 2021; 13(1):116.

PMID: 34034824 PMC: 8146649. DOI: 10.1186/s13148-021-01103-8.

MeCP2 Promotes Colorectal Cancer Metastasis by Modulating ZEB1 Transcription.

Luo D, Ge W Cancers (Basel). 2020; 12(3).

PMID: 32210086 PMC: 7140043. DOI: 10.3390/cancers12030758.

A central role for MeCP2 in the epigenetic repression of miR-200c during epithelial-to-mesenchymal transition of glioma.

Bian E, Chen X, Xu Y, Ji X, Cheng M, Wang H J Exp Clin Cancer Res. 2019; 38(1):366.

PMID: 31429770 PMC: 6702741. DOI: 10.1186/s13046-019-1341-6.

Epigenetic Dysregulation at the Crossroad of Women's Cancer.

Kumar R, Paul A, Rameshwar P, Pillai M Cancers (Basel). 2019; 11(8).

PMID: 31426393 PMC: 6721458. DOI: 10.3390/cancers11081193.

References

Sitruk-Ware R, Plu-Bureau G . Progestins and cancer. Gynecol Endocrinol. 2002; 13 Suppl 4:3-9. DOI: 10.1080/gye.13.s4.3.9. View

Xiong Y, Dowdy S, Podratz K, Jin F, Attewell J, Eberhardt N . Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res. 2005; 65(7):2684-9. DOI: 10.1158/0008-5472.CAN-04-2843. View

Shahbazian M, Antalffy B, Armstrong D, Zoghbi H . Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet. 2002; 11(2):115-24. DOI: 10.1093/hmg/11.2.115. View

Brero A, Easwaran H, Nowak D, Grunewald I, Cremer T, Leonhardt H . Methyl CpG-binding proteins induce large-scale chromatin reorganization during terminal differentiation. J Cell Biol. 2005; 169(5):733-43. PMC: 2171616. DOI: 10.1083/jcb.200502062. View

Ng H, Bird A . DNA methylation and chromatin modification. Curr Opin Genet Dev. 1999; 9(2):158-63. DOI: 10.1016/s0959-437x(99)80024-0. View

Charnock-Jones D, Macpherson A, Archer D, Leslie S, Makkink W, Sharkey A . The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. Hum Reprod. 2000; 15 Suppl 3:85-95. DOI: 10.1093/humrep/15.suppl_3.85. View

Wagner B, Norris J, Knotts T, Weigel N, McDonnell D . The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol. 1998; 18(3):1369-78. PMC: 108850. DOI: 10.1128/MCB.18.3.1369. View

Schotta G, Lachner M, Peters A, Jenuwein T . The indexing potential of histone lysine methylation. Novartis Found Symp. 2004; 259:22-37. View

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

10.

Fujita H, Fujii R, Aratani S, Amano T, Fukamizu A, Nakajima T . Antithetic effects of MBD2a on gene regulation. Mol Cell Biol. 2003; 23(8):2645-57. PMC: 152551. DOI: 10.1128/MCB.23.8.2645-2657.2003. View

11.

Irvine R, Lin I, Hsieh C . DNA methylation has a local effect on transcription and histone acetylation. Mol Cell Biol. 2002; 22(19):6689-96. PMC: 134040. DOI: 10.1128/MCB.22.19.6689-6696.2002. View

12.

Ballestar E, Wolffe A . Methyl-CpG-binding proteins. Targeting specific gene repression. Eur J Biochem. 2000; 268(1):1-6. DOI: 10.1046/j.1432-1327.2001.01869.x. View

13.

Baylin S, Esteller M, Rountree M, Bachman K, Schuebel K, Herman J . Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 2001; 10(7):687-92. DOI: 10.1093/hmg/10.7.687. View

14.

Kumar N, Richer J, Owen G, Litman E, Horwitz K, Leslie K . Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res. 1998; 58(9):1860-5. View

15.

Kleine W, Maier T, Geyer H, Pfleiderer A . Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol. 1990; 38(1):59-65. DOI: 10.1016/0090-8258(90)90012-a. View

16.

Pike M, Pearce C, Wu A . Prevention of cancers of the breast, endometrium and ovary. Oncogene. 2004; 23(38):6379-91. DOI: 10.1038/sj.onc.1207899. View

17.

Vaissiere T, Sawan C, Herceg Z . Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res. 2008; 659(1-2):40-8. DOI: 10.1016/j.mrrev.2008.02.004. View

18.

Tsukada Y, Ishitani T, Nakayama K . KDM7 is a dual demethylase for histone H3 Lys 9 and Lys 27 and functions in brain development. Genes Dev. 2010; 24(5):432-7. PMC: 2827838. DOI: 10.1101/gad.1864410. View

19.

Burnett A, Bahador A, Amezcua C . Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy. Gynecol Oncol. 2004; 94(3):832-4. DOI: 10.1016/j.ygyno.2004.06.004. View

20.

Podratz K, OBrien P, MALKASIAN Jr G, DECKER D, Jefferies J, Edmonson J . Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol. 1985; 66(1):106-10. View